Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population
Cancer Medicine · 2025-03 · 14 (5)
DOI: 10.1002/cam4.70682 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 07.03.2025. Verfasst von Bennett A McIver und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Activities of Daily Living, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Introduction
Symptom burden associated with interference in daily functioning is worse in those with progression or higher‐grade glial tumors. This exploratory study aims to identify factors associated with its severity in a diverse cross‐sectional cohort of 566 brain tumor patients enrolled in a natural history study (NCT03251989, PI: T.S. Armstrong).
Methods
Sociodemographic and clinical data and self‐reported activity‐related interference (work, general activity, walking), mood‐related interference (relations with others, enjoyment of life, mood) were reported via the MD Anderson Symptom Inventory‐Brain Tumor. Activity and mood‐related interference mean scores ≥ 2 were categorized as moderate–severe. Logistic regression assessed univariate associations with moderate–severe interference. Characteristics significant in the univariate analysis were included in a multivariable analysis.
Results
This patient sample had a median age of 48 years (18–85), was mostly male (57%), with a high‐grade tumor (73%), glioblastoma (39%), and tumor recurrence (49%). Risk factors for moderate–severe activity‐related interference included: ≥ 2 surgeries (OR = 1.64, 95% CI [1.10, 2.44], p = 0.015), ependymoma (OR = 2.59, 95% CI [1.21–5.53], p = 0.014), and childhood in a rural area (OR = 1.74, 95% CI [1.15–2.63] p = 0.009). Risk factors for moderate–severe mood‐related interference included tumor progression (OR = 2.02, 95% CI [1.21–3.36], p = 0.009).
Conclusion
Patient reported interference with daily physical functioning is associated with sociodemographic and disease‐related characteristics and notably worse mood‐related interference in those with progression. Future studies should include social determinants of health and change over time to identify and plan interventions for those at risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Bennett A McIver, Tara S Davis, Alvina Acquaye-Mallory, Michelle L Wright
Förderung
- Intramural NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
McIver, B. A., Davis, T. S., Reinhart, K., Vera, E., Acquaye-Mallory, A., Choi, A., Kunst, T., Johnson, M., Grajkowska, E., Miller, H., Reyes, J., Gilbert, M. R., Armstrong, T. S., & Wright, M. L. (2025). Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population. Cancer Medicine, 14(5). https://doi.org/10.1002/cam4.70682
Vancouver
McIver BA, Davis TS, Reinhart K, Vera E, Acquaye-Mallory A, Choi A, et al. Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population. Cancer Medicine. 2025;14(5). doi:10.1002/cam4.70682
BibTeX
@article{McIver2025,
author = {McIver, Bennett A and Davis, Tara S and Reinhart, Kimberly and Vera, Elizabeth and Acquaye-Mallory, Alvina and Choi, Anna and Kunst, Tricia and Johnson, Morgan and Grajkowska, Ewa and Miller, Hope and Reyes, Jennifer and Gilbert, Mark R and Armstrong, Terri S and Wright, Michelle L},
title = {Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {5},
doi = {10.1002/cam4.70682}
}
EUVIMED